ERBB2 and neoplasm: The latest updates of international recommendations for HR+/HER2-negative metastatic breast cancer (MBC) suggest next-generation sequencing of a tumor sample (or plasma circulating tumor DNA, ctDNA) as a standard of care to search for mutations that can be actionable with targeted therapies [16].